{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-253143","form_type":"8-K","ticker":"AVIR","cik":"0001593899","company_name":"Atea Pharmaceuticals, Inc.","filed_at":"2024-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.911908+00:00","generated_at":"2026-05-30T03:34:06.388885+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Atea Q3 net loss $31.2M (-$0.37/sh); COVID-19 Phase 3 fails, HCV topline Dec 2024","bullets":["Net loss $31.2M ($0.37 diluted EPS) vs $33.1M loss ($0.40) YoY; cash $482.8M at Sept 30.","Phase 3 SUNRISE-3 COVID-19 trial missed primary endpoint; no regulatory path pursued.","Phase 2 HCV study (n=275) topline SVR12 results expected early Dec 2024; FDA End-of-Phase 2 meeting planned Q1 2025.","R&D spend $26.2M, down $2.0M YoY due to lower COVID spend offset by higher HCV costs."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-253143","json":"https://secwatch.observer/filing/0001193125-24-253143.json","markdown":"https://secwatch.observer/filing/0001193125-24-253143.md","text":"https://secwatch.observer/filing/0001193125-24-253143.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1593899/000119312524253143/0001193125-24-253143-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1593899/000119312524253143/d841992d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T03:34:06.388885+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}